These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 16447163)

  • 1. Role of Wnts in prostate cancer bone metastases.
    Hall CL; Kang S; MacDougald OA; Keller ET
    J Cell Biochem; 2006 Mar; 97(4):661-72. PubMed ID: 16447163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of Wnts in bone metastases.
    Hall CL; Keller ET
    Cancer Metastasis Rev; 2006 Dec; 25(4):551-8. PubMed ID: 17160558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When prostate cancer meets bone: control by wnts.
    Emami KH; Corey E
    Cancer Lett; 2007 Aug; 253(2):170-9. PubMed ID: 17462819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity.
    Keller ET; Brown J
    J Cell Biochem; 2004 Mar; 91(4):718-29. PubMed ID: 14991763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone.
    Li ZG; Yang J; Vazquez ES; Rose D; Vakar-Lopez F; Mathew P; Lopez A; Logothetis CJ; Lin SH; Navone NM
    Oncogene; 2008 Jan; 27(5):596-603. PubMed ID: 17700537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer cells promote osteoblastic bone metastases through Wnts.
    Hall CL; Bafico A; Dai J; Aaronson SA; Keller ET
    Cancer Res; 2005 Sep; 65(17):7554-60. PubMed ID: 16140917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased Dickkopf-1 expression in breast cancer bone metastases.
    Voorzanger-Rousselot N; Goehrig D; Journe F; Doriath V; Body JJ; Clézardin P; Garnero P
    Br J Cancer; 2007 Oct; 97(7):964-70. PubMed ID: 17876334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases.
    Thudi NK; Martin CK; Murahari S; Shu ST; Lanigan LG; Werbeck JL; Keller ET; McCauley LK; Pinzone JJ; Rosol TJ
    Prostate; 2011 May; 71(6):615-25. PubMed ID: 20957670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism.
    Dai J; Keller J; Zhang J; Lu Y; Yao Z; Keller ET
    Cancer Res; 2005 Sep; 65(18):8274-85. PubMed ID: 16166304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-bone cellular interactions in skeletal metastases.
    Chirgwin JM; Mohammad KS; Guise TA
    J Musculoskelet Neuronal Interact; 2004 Sep; 4(3):308-18. PubMed ID: 15615499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity.
    Kitagawa Y; Dai J; Zhang J; Keller JM; Nor J; Yao Z; Keller ET
    Cancer Res; 2005 Dec; 65(23):10921-9. PubMed ID: 16322239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
    Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
    Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis.
    Vessella RL; Corey E
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6285s-6290s. PubMed ID: 17062715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteolytic prostate cancer cells induce the expression of specific cytokines in bone-forming osteoblasts through a Stat3/5-dependent mechanism.
    Schulze J; Albers J; Baranowsky A; Keller J; Spiro A; Streichert T; Zustin J; Amling M; Schinke T
    Bone; 2010 Feb; 46(2):524-33. PubMed ID: 19796718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone.
    Whang PG; Schwarz EM; Gamradt SC; Dougall WC; Lieberman JR
    J Orthop Res; 2005 Nov; 23(6):1475-83. PubMed ID: 16005175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How Wnt signaling affects bone repair by mesenchymal stem cells from the bone marrow.
    Gregory CA; Gunn WG; Reyes E; Smolarz AJ; Munoz J; Spees JL; Prockop DJ
    Ann N Y Acad Sci; 2005 May; 1049():97-106. PubMed ID: 15965110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells.
    Corey E; Quinn JE; Bladou F; Brown LG; Roudier MP; Brown JM; Buhler KR; Vessella RL
    Prostate; 2002 Jun; 52(1):20-33. PubMed ID: 11992617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis.
    Hall CL; Daignault SD; Shah RB; Pienta KJ; Keller ET
    Prostate; 2008 Sep; 68(13):1396-404. PubMed ID: 18561248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local effects of malignancy on bone.
    Brown SA; Clines GA; Guise TA
    Curr Opin Endocrinol Diabetes Obes; 2007 Dec; 14(6):436-41. PubMed ID: 17982348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dickkopf-1: a suitable target for the management of myeloma bone disease.
    Gavriatopoulou M; Dimopoulos MA; Christoulas D; Migkou M; Iakovaki M; Gkotzamanidou M; Terpos E
    Expert Opin Ther Targets; 2009 Jul; 13(7):839-48. PubMed ID: 19530987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.